US launch 2026!
UP YOUR NOSE AND UP IT GOES LOL!
* It’s also gearing up to launch a new product Roxus, another nasal spray which could help gain access to the US healthcare market
Tylah Tully chats with LTR Pharma (ASX:LTP) executive chairman Lee Rodne about its successful...
Launching in the US early 2026!
* two nasal spray formulations—Spontan and Roxus—both based on the proven compound vardenafil.
* LTR Pharma has announced that it will launch its new product Roxus in the US market in the first half of 2026. Instead of waiting for full regulatory approval...